Behaviour of Crohn s disease according to the Vienna classification: changing pattern over the course of the disease

Size: px
Start display at page:

Download "Behaviour of Crohn s disease according to the Vienna classification: changing pattern over the course of the disease"

Transcription

1 Gut 2001;49: Department of Gastroenterology, University Hospital of Liège, Belgium E Louis A Collard A F Oger E Degroote F Aboul Nasr El Yafi J Belaiche Correspondence to: E Louis, Service de Gastroentérologie, CHU de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium. edouard.louis@ulg.ac.be Accepted for publication 3 July 2001 Behaviour of Crohn s disease according to the Vienna classification: changing pattern over the course of the disease E Louis, A Collard, A F Oger, E Degroote, F Aboul Nasr El Yafi, J Belaiche Abstract Background Crohn s disease is a heterogeneous disorder with both a genetic and environmental aetiology. Clinical classifications of the disease, such as the newly proposed Vienna classification, may help to define subgroups of patients suitable for studying the influence of specific genetic or environmental factors. Aim To assess the stability over the course of the disease of its location and behaviour, as determined according to the Vienna classification. Patients and methods The notes of 297 Crohn s disease patients regularly followed up at our institution were carefully reviewed retrospectively. The behaviour and location of the disease according to the Vienna classification were determined at diagnosis and after 1, 3, 5, 10, 15, 20, and 25 years of follow up. The proportions of the diverent behaviours and locations of the disease were calculated at these time points. A statistical analysis of the evolution of these characteristics over 10 years was performed on a subgroup of 125 patients with at least 10 years of follow up. The influence of age at diagnosis on location and behaviour of the disease was assessed as well as the influence of location on the behaviour of the disease. Results The location of the disease remained relatively stable over the course of the disease. Although the proportion of patients who had a change in disease location became statistically significant after five years (p=0.01), over 10 years only 15.9% of patients had a change in location (p<0.001). We observed a more rapid and prominent change in disease behaviour, which was already statistically significant after one year (p=0.04). Over 10 years, 45.9% of patients had a change in disease behaviour (p<0.0001). The most prominent change was from non-stricturing non-penetrating disease to either stricturing (27.1%; p<0.0001) or penetrating (29.4%; p<0.0001) disease. Age at diagnosis had no influence on either location or behaviour of disease. Ileal Crohn s disease was more often stricturing, and colonic or ileocolonic Crohn s disease was more often penetrating: this was already the case at diagnosis and became more prominent after 10 years (p<0.05). Conclusions Location of Crohn s disease, as defined by the Vienna classification, is a relatively stable phenotype which seems suitable for phenotypegenotype analyses. Behaviour of Crohn s disease according to the Vienna classification varies dramatically over the course of the disease and cannot be used in phenotype-genotype analyses. The potential influence of genes on the behaviour of Crohn s disease should be studied in subgroups of patients defined by their disease behaviour after a fixed duration of disease. (Gut 2001;49: ) Keywords: Crohn s disease; genetics; Vienna classification Crohn s disease is a multifactorial polygenic disease with probable genetic heterogeneity. 1 In this hypothesis, diverent genetic backgrounds may explain diverent clinical patterns of the disease. 2 Thus apart from specific disease predisposing genes, such as the recently described Nod 2, 3 4 some disease modifying genes may also exist. Various disease phenotypes that may be genetically determined have been suggested. 5 These include age at diagnosis, sex, family history, location of disease, response to treatment, and what has been called behaviour of disease. To date few data, largely uncorroborated, have been published on the genetics of these phenotypes. 6 9 This may be due to the complexity of the genetic model and to the large number of possible candidate genes for the various characteristics of the disease as well as interference from environmental influences. However, the main problem with these studies may be the irrelevance of the phenotypes studied. To be considered possibly genetically determined, a phenotype should be stable over time. Obviously this is the case for age at diagnosis and sex, but for the other characteristics, in particular location and behaviour of disease, stability of the phenotypes remains to be proved. Behaviour of disease first referred to the indication for surgery: either perforating or non-perforating disease. 10 These definitions were extended to non-surgical situations and behaviour was then termed as: primarily penetrating, primarily fibrostenotic, or primarily inflammatory, depending on the dominating feature at a given point in time. 11 However, penetrating and fibrostenotic features often

2 778 Louis, Collard, Oger, et al coexist and this classification proved to be difficult to reproduce. 12 A new classification based on disease behaviour was then proposed at the 1998 world gastroenterology meeting in Vienna. 13 In this classification system, a hierarchy was introduced for stricturing and penetrating complications to try and improve reproducibility. Some arguments exist for a fixed disease behaviour in individual patients, including indications for surgery and relative conservation of disease behaviour in multiply avected families However, the stability of disease behaviour over the course of the disease has never been studied specifically using a standardised classification. Location of disease is another characteristic that could be genetically determined, at least in part. In common with disease behaviour, some conservation of this character has been described in multiply avected families Furthermore, specific disease locations have been linked to serological or genetic markers such as antineutrophil antibodies. Again, the Vienna classification system has proposed some modifications in an attempt to produce more relevant and stable categories. 13 Furthermore, as it was considered that intestinal resection would significantly interfere with the spontaneous location of the disease, characterisation of disease location was decided before the first surgical procedure. As for disease behaviour, it remains unclear whether these newly defined phenotypes represent stable phenotypes suitable for genotype-phenotype association studies. Therefore, the aim of our work was to assess the evolution over time of behaviour and location of Crohn s disease, as defined by the Vienna classification. In particular, we wished to examine stable characters that may be relevant for genetic studies. Patients and methods CLASSIFICATION OF PATIENTS From a computed database of 500 patients with Crohn s disease seen at our university hospital, we selected 297 patients who were regularly followed up in our gastroenterology department. We then reviewed the medical notes of these 297 patients. For each patient, we determined current A (age at diagnosis), L (location), and B (behaviour) status of the Vienna classification 13 (table 1). We then retrospectively determined LB status at diagnosis, and after 1, 3, 5, 10, 15, 20, and 25 years of evolution. According to the Vienna classification, patients were defined as A1 if the diagnosis was made before 40 years of age and A2 if it was made thereafter. L1 corresponds to disease Table 1 Age at diagnosis Location Behaviour The Vienna classification of Crohn s disease A1, <40 years A2, >40 years L1, Terminal ileum L2, Colon L3, Ileocolon L4, Upper gastrointestinal B1, non-stricturing non-penetrating B2, Stricturing B3, Penetrating located in the terminal ileum (possibly involving the caecum), L2 in the colon, L3 ileocolon, and L4 involving the upper gastrointestinal tract (irrespective of the other locations of the disease). Location of disease is defined by the maximal extent of the disease but in case of surgical resection during the course of the disease, it is determined before the first resection. B1 corresponds to a non-stricturing nonpenetrating disease, B2 stricturing, and B3 penetrating. A disease is classified as B3 as soon as there are intra-abdominal or perianal fistula, perianal ulcer, inflammatory mass, and/or abscess at any time during the course of the disease, even if there are coexisting strictures. According to this classification, unlike that for location, the behaviour category of the disease was not decided after the first surgery and no specific limit during the course of the disease was imposed to define it. We also classified patients for behaviour and location depending on age classification and for behaviour depending on location. Age at diagnosis was usually easy to find in the medical notes of the patients. For location of disease, we used x ray and endoscopy protocols as well as surgical reports. For disease behaviour, we used x ray, computed tomography scan, magnetic resonance imaging, ultrasound, and endoscopy protocols as well as proctology and surgical reports. When data were missing or unclear, the item was unclassified until more recent data were available. EXPRESSION OF RESULTS AND STATISTICS In the description of our population according to the Vienna classification criteria at the last visit, the proportion of patients in the various categories as well as the percentage of unclassified patients are given. In all other results the percentage of unclassified patients are no longer given and the proportions are calculated on the number of classified patients to avoid the influence of the number of unclassified patients on the percentages observed in the various categories. There were few data missing at the diverent time points, never exceeding 3% of patients. To check for a statistically significant trend in disease behaviour or change in location, we tested the hypothesis of a proportion of change diverent from 0 between diagnosis and 10 years of evolution in a subgroup of 125 patients with a follow up of at least 10 years. The proportion was considered statistically significant when the ratio between the observed proportion and standard error was greater than 1.96 (p<0.05). In the description of disease behaviour and change in location over 10 years in the 125 patients, duration before change is given as median (range). When we studied the influence of age at diagnosis on behaviour and location of disease, as well as the influence of location on behaviour of disease, we compared percentages of patients in the various categories using Fisher s exact test with a level of significance set at p<0.05.

3 Behaviour of Crohn s disease according to Vienna classification 779 Table 2 Classification B (behaviour) and L (location) (%) at diagnosis and at diverent time points in the course of the disease (years) Disease duration (y) (n=297) (n=259) (n=218) (n=187) (n=125) (n=74) (n=47) (n=32) B B B L L L L Results ABL CLASSIFICATIONS AT THE LAST VISIT We had recent clinical data (within the last two years) for 264 of the 297 patients studied. Median follow up at the last visit for these patients was 9 years (2 months 34 years). The proportions of patients in the diverent classifications according to items A, L, and B of the Vienna system were as follows: A1, 83.5%; A2, 16.5%; L1, 37.5%; L2, 21.6%; L3, 32.9%; L4, 5.7%; L?, 2.3%; B1, 28%; B2, 27.7%; B3, 43.2%; B?, 1.1%. BL CLASSIFICATIONS AT DIAGNOSIS AND AT DIFFERENT TIME POINTS IN THE COURSE OF THE DISEASE We had clinical data for classification at diagnosis for all 297 patients. The numbers of patients available for classification at 1, 3, 5, 10, 15, 20, and 25 years over the course of the disease were 259, 218, 187, 125, 74, 47, and 25, respectively. Evolution over time of the proportion of patients classified according to items L and B of the Vienna classification are shown in table 2. There was a dramatic change in the proportion of various disease behaviours while the change in distribution of disease location was minimal. When examining the rate of change in behaviour over time, and particularly the rate of appearance of complicated forms, we found 26.3% of patients with disease behaviour B2 and B3 at diagnosis, 29.5% of initially B1 patients became B2 or B3 from diagnosis to five years, 43.1% from five to 10 years, 27.3% from 10 to 15 years, 10% from 15 to 20 years, and 33.3% from 20 to 25 years. These proportions were not significantly diverent. Examining exclusively the change from B2 to B3, fewer diverences were observed. Overall, 91 patients were classified as B2 at some time point in their evolution: 33 were classified as B2 at diagnosis and 58 were classified as B1 and became B2 over time. Among these patients the majority (78%) remained B2 (median follow up 6.5 years (range 1 32)). In particular, in patients who were classified as B2 at diagnosis, 88% remained as B2 (median follow up 7 years (1 30)). INFLUENCE OF SURGERY ON EVOLUTION OF DISEASE BEHAVIOUR In total, 68 patients underwent surgery and the proportion of patients who had surgery over a 10 year period was 30.4% (38 of 125 patients with at least 10 years of follow up). At the time B1 B2 B3 0 Diagnosis 5 years 10 years Figure 1 Evolution of disease behaviour according to the Vienna classification system over 10 years in 125 patients with Crohn s disease. The proportion of patients with non-stricturing non-penetrating (B1), stricturing (B2), and penetrating (B3) disease are shown at diagnosis, and after five and 10 years of evolution. The proportion of patients with a change in disease behaviour was highly significant over 10 years (p<0.0001) and was already significantly diverent from zero after one year (p=0.04). of surgery, 14 were classified as B1, 31 as B2, and 23 as B3. After surgery, 3/14 patients with a classification of B1 remained B1, eight became B2, and three became B3 (median follow up 7 years (1 20)); 24/31 patients with a classification of B2 remained B2, while seven became B3 (median follow up 8 years (1 25)). EVOLUTION OF B AND L CLASSIFICATIONS IN A POPULATION OF 125 PATIENTS OVER 10 YEARS OF FOLLOW UP Among these 125 patients, we had complete data on behaviour and location at all time points for 109 patients. Evolution of B and L classifications over 10 years for these 109 patients is shown in figs 1 and 2. The proportion of patients changing from B1 to B2 was 27.1%, with a median duration before change of 5.5 years (4 months 10 years). The proportion of change from B1 to B3 was 29.4%, with a median duration before change of 6 years (1 10). The proportion of initially B2 patients changing from B2 to B3 was 15.4% L1 L2 L3 L4 0 Diagnosis 5 years 10 years Figure 2 Evolution of disease location according to the Vienna classification system over 10 years in 125 patients with Crohn s disease. The proportion of patients with ileal (L1), colonic (L2), ileocolonic (L3), and upper gastrointestinal (L4) disease are shown at diagnosis, and after five and 10 years of evolution. The proportions of patients with a change in disease location was statistically significant over 10 years (p<0.001). This proportion became significantly diverent from zero after five years (p=0.01).

4 780 Louis, Collard, Oger, et al Table 3 L (location) and B (behaviour) categories (%) of the Vienna classification at diagnosis according to age (A). There was no significant diverence between subgroups A1 and A2 A1 (n=248) L L L L B B B A2 (n=49) (only 2/13 patients, after 3.5 and 4.5 years). Overall, after 10 years of evolution, 45.9% of patients had a change in behaviour and this proportion was already significant after one year (3.7%; p=0.04). Examining diverent types of changes in disease behaviour, the only significant change, even after 10 years, was that from B2 to B3 (p=0.15). The proportion of patients with a change in disease location from L1 to another location was 20.3% (83.3% to L3), with a median duration before change of 5.5 years (2.3 10). The proportion of patients initially L2 changing to L3 or L4 was 16.7% (100% to L3), with a median duration before change of 7.5 years (1 10). The proportion of patients initially L3 changing to L4 was 4.8% (1/21; change after 8.3 years). Overall, after 10 years of evolution, 15.9% had a change in location and this proportion became significant only after five years (7.9%; p=0.01). BL CLASSIFICATION ACCORDING TO A A total of 248 (83.5%) patients were diagnosed with Crohn s disease before 40 years of age (A1) and 49 (16.5%) after this age (A2). The BL classification at diagnosis for these patients is shown in table 3. There was no significant diverence between A1 and A2 patients. In both subgroups (A1 and A2), as in the overall population, there was a decreased proportion of patients classified as B1 and an increased proportion of B2 and B3 classifications over time, while location of disease remained more stable. The subgroup of A2 patients was too small however (only 10 patients with at least 10 years of follow up) to perform any comparison. B CLASSIFICATION ACCORDING TO L B classification according to L at diagnosis and after 10 years of evolution is shown in table 4. At diagnosis, there was significantly more penetrating and less stricturing disease in pure colonic (L2) than in pure ileal (L1) locations. This was even more prominent after 10 years of evolution. Discussion Using the new Vienna classification of Crohn s disease in this retrospective study, we have shown striking changes in disease behaviour over the course of the disease while disease location remained relatively stable. This changing disease behaviour was significantly influenced by the location of the disease but not by age at diagnosis. As it becomes clear that Crohn s disease represents a heterogeneous entity, 2 it is of paramount importance to disclose stable and reproducible phenotypes in order to study their genetic or environmental basis. Location and behaviour of Crohn s disease are important features of the disease but their stability over the course of the disease had not been demonstrated. We found good stability of disease location, defined according to the Vienna classification. Although the trend toward a changing pattern was statistically significant after five years of evolution, overall (over 10 years) about 85% of patients did not show a change. This relative stability has previously been suggested, even using slightly diverent definitions of disease location, 5 although some changes may also be observed. 22 During its course a disease can extend or regress within the same region and this will not change its classification according to the Vienna system. It can also regress or extend to another region. According to our results this does not seem to occur frequently. The main change we observed was from ileal (L1) or colonic (L2) to ileocolonic disease (L3). Over 10 years however it involved less than one fifth of patients with pure ileal or pure colonic disease at diagnosis. The frequency of upper gastrointestinal lesions was rare at diagnosis and few patients seemed to develop these over the course of the disease. This relative stability may be due to the retrospective character of the study and the absence of a systematic search for extension. However, in our population, median duration since the last exploration (by x ray or endoscopy) of disease extent was 2.5 years suggesting that the results analysed over 10 or 25 years were probably realistic. These data indicated that disease location, according to the Vienna classification, may be determined by some stable environmental or genetic influences and that it probably represents a relevant characteristic in phenotypegenotype studies. In contrast, we found dramatic changes in behaviour over the course of the disease. This is the first time that this changing pattern has been clearly demonstrated, despite the fact that we used a classification system considered to Table 4 B (behaviour) categories (%) of the Vienna classification according to L (location) at diagnosis and after 10 years of evolution Diagnosis After 10 y L1 (n=121) L2 (n=68) L3 (n=66) L4 (n=11) L1 (n=51) L2 (n=25) L3 (n=60) L4 (n=4) B B ** ** 25 B ** 15.2* * 60** 25 *p<0.05; **p<0.01, L2 or L3 compared with L1.

5 Behaviour of Crohn s disease according to Vienna classification 781 have good interobserver reproducibility. 13 This changing pattern over time was suggested previously in the initial publication of the Vienna classification as diverence in behaviour proportions were described in populations with diverent durations of follow up. 13 In our population, while the majority of patients had uncomplicated non-stricturing nonpenetrating disease (B1) at diagnosis, very few had uncomplicated disease after 25 years of follow up. Furthermore, the rate of change from B1 to either the stricturing (B2) or penetrating (B3) phenotype remained stable over 25 years and did not seem to decrease over time, with approximately 25 33% of B1 patients changing to B2 or B3 every five years. This suggests that in our population, if followed for long enough, virtually all patients with Crohn s disease would develop either stricturing or penetrating disease. This however may reflect a particular severity of our Crohn s disease patients in an academic referral centre. Our data did not allow us to establish a duration of the disease after which it would be unlikely for disease behaviour to change. However, when considering stricturing disease, it is striking that the majority of patients develop this pattern within 10 years and that only a minority progress to a penetrating disease. The development of a stricturing or penetrating behaviour probably represents a multifactorial phenomenon involving both environmental (including disease treatment) and genetic factors. Therefore, genetic factors may be more important in the speed at which a penetrating or stricturing behaviour develops than in the ultimate behaviour of the disease. Indeed, one could imagine that certain aspects of connective tissue metabolism are genetically determined and may influence the occurrence of stricturing or penetrating complications. 23 We did not find any significant diverence in disease behaviour or location in relation to age at diagnosis. In the first paper on the Vienna classification, a diverence in disease location but not behaviour was found. 13 This discrepancy regarding disease location may be due to the fact that we had a relatively small number of patients with a diagnosis later than 40 years of age (A2), rendering statistical analysis on this subgroup diycult. Our data also showed that the change in disease behaviour over time and relative stability of disease location were found both in A1 and A2 patients, suggesting that this changing pattern of Crohn s disease behaviour was not linked to age at diagnosis. The final point we studied was the association between disease location and behaviour as well as the influence of disease location on disease behaviour evolution. A positive association between location and behaviour was found previously in the original description of the Vienna classification. 13 As in this previous work we found an association between isolated small bowel location (L1) and stricturing disease (B2), and between colonic disease (L2) and penetrating behaviour (B3). This association was present at diagnosis and was quantitatively more prominent after 10 years. In contrast with the first paper however, in our population ileocolonic disease (L3) was also more often penetrating (B3) than stricturing (B2). This was only true after 10 years of evolution and not at diagnosis. Thus this diverence from the previous study may be linked to variable duration of disease at the time of classification. The association between stricturing disease and small bowel location was previously described using diverent classifications. 24 Apart from these previously described associations, our data also showed that changes in disease behaviour over time were noted in the various locations of the disease. In conclusion, we have demonstrated dramatic and sustained changes in Crohn s disease behaviour over time while disease location remained more stable. Hence if location of disease, as defined by the Vienna classification, can be used in genotype-phenotype analyses, this is not the case for behaviour of the disease. Nevertheless, the rate of appearance of stricturing or penetrating complications of the disease may still be genetically determined. Therefore, for genotype-behavioural phenotype analyses, patients should be classified either after a fixed duration of disease or in categories according to the rate of appearance of stricturing or penetrating complication. E Louis is a Research Associate at the FNRS Belgium. 1 Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115: Cho JH, Brant SR. Genetics and genetic markers in inflammatory bowel disease. Curr Opin Gastroenterol 1998;14: Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn s disease.nature2001;411: Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn s disease. Nature 2001;411: Sutherland LR. DiVerent patterns of Crohn s disease. In: Prantera C, Korelitz B, eds. Crohn s disease. New York: Marcel Dekker, Inc., 1996: Heresbach D, Alizadeh M, Bretagne JF, et al. TAP gene transporter polymorphism in inflammatory bowel diseases. Scand J Gastroenterol 1997;32: Plevy SE, Taylor K, De Woody KL, et al. Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody (panca) identify Crohn s disease (CD) patients with poor clinical response to anti-tnf monoclonal antibody (ca2). Gastroenterology 1997;112:A Bouma G, Poen AC, Garcia-Gonzalez MA, et al. HLA- DRB1*03, but not the TNFA-308 promoter gene polymorphism, confers protection against fistulising Crohn s disease. Immunogenetics 1998;47: Louis E, Peeters M, Franchimont D, et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn s disease: influence on disease behaviour? Clin Exp Immunol 2000; 119: Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn s disease: evidence for two clinical forms. Gut 1988; 29: Sachar DB, Adrews HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn s disease. Gastroenterol Int 1992;5: Steinhart AH, Girgrah N, McLeod RS. Reliability of a Crohn s disease clinical classification scheme based on disease behavior. Inflamm Bowel Dis 1998;4: Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn s disease: report of the working party of the world congresses of gastroenterology,vienna Inflamm Bowel Dis 2000;6: Aeberhard P, Berchtold W, Riedtmann HJ, et al. Surgical recurrence of perforating and nonperforating Crohn s disease: a study of 101 surgically treated patients. Dis Colon Rectum 1996;39: Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn s disease. Gastroenterology 1998;115:

6 782 Louis, Collard, Oger, et al 16 Yamamoto T, Allan RN, Keighley MR. Perforating ileocecal Crohn s disease does not carry a high risk of recurrence but usually re-presents as perforating disease. Dis Colon Rectum 1999;42: Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn s disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996;111: Bayless TM, Tokayer AZ, Polito JM II, et al. Crohn s disease: concordance for site and clinical type in avected family members potential hereditary influences.gastroenterology 1996;111: Satsangi J, Grootscholten C, Holt H, et al. Clinical patterns of familial inflammatory bowel disease. Gut 1996;38: Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn s disease define a clinical subgroup. Gastroenterology 1996;110: Satsangi J, Landers CJ, Welsh KI, et al. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998;4: Peschard S, Beaugerie L, Carbonnel F, et al. La maladie de Crohn iléale pure reste-t-elle toujours localisée? Gastroenterol Clin Biol 1998;22:A Gilberts EC, Greenstein AJ, Katsel P, et al. Molecular evidence for two forms of Crohn s disease. Proc Natl Acad Sci USA 1994;91: Farmer RG, Hawk WA, Turnbull RB. Indications for surgery in Crohn s disease. An analysis of 500 cases. Gastroenterology 1976;71: Gut: first published as /gut on 1 December Downloaded from on 12 May 2018 by guest. Protected by copyright.

Crohn s disease is a heterogeneous inflammatory disorder

Crohn s disease is a heterogeneous inflammatory disorder ORIGINAL ARTICLE Application of the Montreal classification for Crohn s disease to a single clinician database of 1015 patients Hugh J Freeman MD HJ Freeman. Application of the Montreal classification

More information

Disease behavior in adult patients- are there predictors for stricture or fistula formation?

Disease behavior in adult patients- are there predictors for stricture or fistula formation? Disease behavior in adult patients- are there predictors for stricture or fistula formation? Falk Symposium 168, Madrid, Spain Iris Dotan, M.D., Head, IBD Center, Department of Gastroenterology and Liver

More information

The cause of ulcerative colitis (UC) and Crohn s disease

The cause of ulcerative colitis (UC) and Crohn s disease GASTROENTEROLOGY 2003;124:1767 1773 Inflammatory Bowel Disease in a Swedish Twin Cohort: A Long- Term Follow-up of Concordance and Clinical Characteristics JONAS HALFVARSON,* LENNART BODIN, CURT TYSK,*

More information

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight

More information

Fibrotic complications of inflammatory bowel disease

Fibrotic complications of inflammatory bowel disease January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fibrotic complications of inflammatory bowel disease Gerhard Rogler, Department of Gastroenterology

More information

Crohn disease is a chronic inflammatory bowel disease

Crohn disease is a chronic inflammatory bowel disease GASTROENTEROLOGY 2010;139:1147 1155 Risk Factors Associated With Progression to Intestinal Complications of Crohn s Disease in a Population-Based Cohort KELVIN T. THIA,*, WILLIAM J. SANDBORN,* WILLIAM

More information

Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease

Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease Vinna An, Ashwinna Asairinachan, Michael Johnston, James Keck, Paul Salama, Steven Brown, Rodney Woods Department of Colorectal

More information

HLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER

HLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER HLA TYPING AND EXPRESSION: POTENTIAL MARKER FOR IDENTIFYING EARLY DYSPLASIA AND STRATIFYING THE RISK FOR IBD-CANCER Megan Garrity, S. Breanndan Moore, M.D., William Sandborn, M.D., Vernon Pankratz, Ph.D.,

More information

Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University.

Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University. Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University. Chronic transmural inflammatory process of the bowel & affects any part of the gastro -intestinal tract from the mouth to the

More information

Edinburgh Research Explorer

Edinburgh Research Explorer Edinburgh Research Explorer The Montreal classification of inflammatory bowel disease Citation for published version: Satsangi, J, Silverberg, MS, Vermeire, S & Colombel, J-F 2006, 'The Montreal classification

More information

CARD15 Gene Mutations and Risk for Early Surgery in Pediatric-Onset Crohn s Disease

CARD15 Gene Mutations and Risk for Early Surgery in Pediatric-Onset Crohn s Disease CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:1003 1009 CARD15 Gene Mutations and Risk for Early Surgery in Pediatric-Onset Crohn s Disease SUBRA KUGATHASAN,* NICOLE COLLINS,* KAREN MARESSO, RAYMOND

More information

C Gasche, P Grundtner

C Gasche, P Grundtner 162 Recent advances in clinical practice GENOTYPES AND PHENOTYPES IN CROHN S DISEASE: DO THEY HELP IN CLINICAL MANAGEMENT? c CROHN S See end of article for authors affiliations Correspondence to: Professor

More information

Crohn s Disease: A New Approach to an Old Problem

Crohn s Disease: A New Approach to an Old Problem Management of Postoperative Crohn s Disease: A New Approach to an Old Problem Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center

More information

GRANULOMATOUS COLITIS: SIGNIFICANCE OF INVOLVEMENT OF THE TERMINAL ILEUM

GRANULOMATOUS COLITIS: SIGNIFICANCE OF INVOLVEMENT OF THE TERMINAL ILEUM GASTROENTEROLOGY 64: 1071-1076, 1973 Copyright 1973 by The Williams & Wilkins Co. Vol. 64, No.6 Printed in U.S.A. GRANULOMATOUS COLITIS: SIGNIFICANCE OF INVOLVEMENT OF THE TERMINAL ILEUM JAMES A. NELSON,

More information

Running head: CHRON'S DISEASE GENE-ENVIRONMENTAL INTERACTION 1

Running head: CHRON'S DISEASE GENE-ENVIRONMENTAL INTERACTION 1 Running head: CHRON'S DISEASE GENE-ENVIRONMENTAL INTERACTION 1 A review of Crohn's Disease Gene-Environmental Interaction A study of gene-environment interaction between genetic susceptibility variants

More information

Crohn disease (CD) is a heterogeneous chronic idiopathic

Crohn disease (CD) is a heterogeneous chronic idiopathic ORIGINAL ARTICLE The Epidemiology and Phenotype of Crohn s Disease in the Chinese Population Rupert W.L. Leong, MBBS,* James Y. Lau, MBBS, MD, and Joseph J.Y. Sung, MBBS, MD, PhD Background: Inflammatory

More information

I n recent years it has been firmly established that anti-

I n recent years it has been firmly established that anti- 1237 INFLAMMATORY BOWEL DISEASE Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease J Halfvarson, A Standaert-Vitse, G Järnerot, B Sendid, T Jouault, L Bodin, A Duhamel, J

More information

Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R.

Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R. UvA-DARE (Digital Academic Repository) Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R. Link to publication Citation for published version

More information

Research Article Temporary Fecal Diversion in the Management of Colorectal and Perianal Crohn s Disease

Research Article Temporary Fecal Diversion in the Management of Colorectal and Perianal Crohn s Disease Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2015, Article ID 286315, 5 pages http://dx.doi.org/10.1155/2015/286315 Research Article Temporary Fecal Diversion in the Management

More information

The Natural History of Fistulizing Crohn s Disease in Olmsted County, Minnesota

The Natural History of Fistulizing Crohn s Disease in Olmsted County, Minnesota GASTROENTEROLOGY 2002;122:875 880 CLINICAL RESEARCH The Natural History of Fistulizing Crohn s Disease in Olmsted County, Minnesota DAVID A. SCHWARTZ,* EDWARD V. LOFTUS, JR.,* WILLIAM J. TREMAINE,* REMO

More information

World Journal of Colorectal Surgery

World Journal of Colorectal Surgery World Journal of Colorectal Surgery Volume 6, Issue 5 2016 Article 4 Isolated Jejunal Crohn s Disease, A Diagnostic Dilemma Elise Biesboer BS Lacey Stelle MD Michelle M. Olson MD, MACM Paul Tender MD University

More information

Previous reports have suggested that youngonset

Previous reports have suggested that youngonset R E S E A R C H B R I E F Age-related Differences in the Clinical Course of Crohn s Disease in an Asian Population: A Retrospective Cohort Review SIU-TONG LAW AND KIN KONG LI From Department of Medicine

More information

Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis

Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis The Harvard community has made this article openly available. Please share how this access benefits you. Your

More information

Crohn s disease is a chronic recurrent inflammation of the

Crohn s disease is a chronic recurrent inflammation of the CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:1430 1438 Clinical Course in Crohn s Disease: Results of a Norwegian Population-Based Ten-Year Follow-Up Study INGER CAMILLA SOLBERG,* MORTEN H. VATN, OLE

More information

D espite the apparent increase in incidence of childhood

D espite the apparent increase in incidence of childhood 995 ORIGINAL ARTICLE Presenting features of inflammatory bowel disease in Great Britain and Ireland A Sawczenko, B K Sandhu... See end of article for authors affiliations... Correspondence to: Professor

More information

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel

More information

T he treatment strategy for Crohn s disease (CD) is

T he treatment strategy for Crohn s disease (CD) is 237 INFLAMMATORY BOWEL DISEASE Impact of the increasing use of immunosuppressants in Crohn s disease on the need for intestinal surgery J Cosnes, I Nion-Larmurier, L Beaugerie, P Afchain, E Tiret, J-P

More information

Ulcerative colitis (UC) and Crohn s disease (CD) are 2

Ulcerative colitis (UC) and Crohn s disease (CD) are 2 ORIGINAL ARTICLE Smoking and Inflammatory Bowel Disease: Trends in Familial and Sporadic Cohorts Jeffrey A. Tuvlin,MD,* Sania S. Raza, BA, Samuel Bracamonte, BA, Christina Julian, BA, Stephen B. Hanauer,

More information

A Case of Inflammatory Bowel Disease

A Case of Inflammatory Bowel Disease A Case of Inflammatory Bowel Disease Dr Barrie Rathbone www.le.ac.uk 26 year old Polish woman Admitted as emergency under surgeons RUQ and RIF pain Abdominal pain had occurred intermittently for a few

More information

The inflammatory bowel diseases (IBD), Crohn s disease

The inflammatory bowel diseases (IBD), Crohn s disease GASTROENTEROLOGY 2008;135:1114 1122 Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel Disease JOHAN VAN LIMBERGEN,*,,# RICHARD K. RUSSELL, HAZEL E. DRUMMOND,* MARIAN C. ALDHOUS,*

More information

HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis

HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis Gut 999;4:9 40 9 Laboratory for Experimental Internal Medicine, Academic Medical Centre, G2 0, Meibergdreef 9, 0 AZ Amsterdam, The Netherlands P C F Stokkers P H Reitsma GNJTytgat SJHvanDeventer Correspondence

More information

11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery

11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)

More information

WORKING PARTY REPORT. Can J Gastroenterol Vol 19 Suppl A September 2005

WORKING PARTY REPORT. Can J Gastroenterol Vol 19 Suppl A September 2005 WORKING PARTY REPORT Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

More information

The Best of IBD at UEGW (Crohn s)

The Best of IBD at UEGW (Crohn s) The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best

More information

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human

More information

Sex stratification of an inflammatory bowel disease genome search shows male-specific linkage to the HLA region of chromosome 6

Sex stratification of an inflammatory bowel disease genome search shows male-specific linkage to the HLA region of chromosome 6 (2002) 10, 259 ± 265 ã 2002 Nature Publishing Group All rights reserved 1018-4813/02 $25.00 www.nature.com/ejhg ARTICLE Sex stratification of an inflammatory bowel disease genome search shows male-specific

More information

Crohn s disease is a heterogeneous inflammatory disorder. Long-term clinical behaviour of jejunoileal involvement in Crohn s disease ORIGINAL ARTICLE

Crohn s disease is a heterogeneous inflammatory disorder. Long-term clinical behaviour of jejunoileal involvement in Crohn s disease ORIGINAL ARTICLE ORIGINAL ARTICLE Long-term clinical behaviour of jejunoileal involvement in Crohn s disease Hugh J Freeman MD HJ Freeman. Long-term clinical behaviour of jejunoileal involvement in Crohn s disease. Can

More information

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel

More information

Does Anastomosis Configuration Influence Long-term Outcomes in Patients With Crohn Disease?

Does Anastomosis Configuration Influence Long-term Outcomes in Patients With Crohn Disease? Original Article Ann Coloproctol 217;33(5):173-177 https://doi.org/1.3393/ac.217.33.5.173 pissn 2287-9714 eissn 2287-9722 Does Anastomosis Configuration Influence Long-term Outcomes in Patients With Crohn

More information

Differentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics

Differentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics 38 Original Article Differentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics Anuchapreeda S Leelakusolvong S Charatcharoenwitthaya

More information

Evidence for Association of OCTN Genes and IBD5 with Ulcerative Colitis. for Medical Research, University of Cambridge, Cambridge, UK

Evidence for Association of OCTN Genes and IBD5 with Ulcerative Colitis. for Medical Research, University of Cambridge, Cambridge, UK Gut Online First, published on December 16, 2005 as 10.1136/gut.2005.084574 Evidence for Association of OCTN Genes and IBD5 with Ulcerative Colitis Sarah Waller 1, Mark Tremelling 1, Francesca Bredin 1,

More information

YES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)

YES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) Stage I: Rule-Out Dashboard GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome HGNC ID: 6670, 1076 OMIM ID: 174900, 175050 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,

More information

Prevention and Management of Postoperative Crohn s disease

Prevention and Management of Postoperative Crohn s disease Prevention and Management of Postoperative Crohn s disease Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center Director, Gastroenterology,

More information

European evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management

European evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management European evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management J. Martin-Comin Hospital U. Bellvitge Hospitalet de Llobregat Spain THE EUROPEAN

More information

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases? How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases? Alessandro Armuzzi Lead IBD Unit Complesso Integrato Columbus Fondazione Policlinico Gemelli Università

More information

Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv

Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv University 1 SHARE study My year Collaboration between gastroenterology

More information

Personalized Medicine in IBD: Where Are We in 2013

Personalized Medicine in IBD: Where Are We in 2013 Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized

More information

Towards Precision Medicine in Inflammatory Bowel Diseases

Towards Precision Medicine in Inflammatory Bowel Diseases Precision Medicine and Biomarkers Leaders Summit. Munich September 13-14, 2018 Towards Precision Medicine in Inflammatory Bowel Diseases ANDRÉS HURTADO-LORENZO, Ph.D. SENIOR DIRECTOR OF TRANSLATIONAL RESEARCH

More information

Personalized Medicine in IBD

Personalized Medicine in IBD Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016

More information

THE OUTCOME OF INFLAMMATORY BOWEL DISEASE

THE OUTCOME OF INFLAMMATORY BOWEL DISEASE THE OUTCOME OF INFLAMMATORY BOWEL DISEASE R G Farmer SING MED J. 1989; No 3: 89-93 Crohn's disease and ulcerative colitis have become among the most frequently encountered chronic digestive diseases. Two

More information

Ileo-rectal anastomosis for Crohn's disease of

Ileo-rectal anastomosis for Crohn's disease of Ileo-rectal anastomosis for Crohn's disease of the colon W. N. W. BAKER From the Research Department, St Mark's Hospital, London Gut, 1971, 12, 427-431 SUMMARY Twenty-six cases of Crohn's disease of the

More information

INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL

INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University

More information

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification

More information

children Crohn s disease in MR enterography for GI Complications Microscopy Characterization Primary sclerosing cholangitis Anorectal fistulae

children Crohn s disease in MR enterography for GI Complications Microscopy Characterization Primary sclerosing cholangitis Anorectal fistulae MR enterography for Crohn s disease in children BOAZ KARMAZYN, MD PEDIATRIC RADIOLOGY ASSOCIATE PROFESSOR Characterization Crohn disease Idiopathic chronic transmural IBD Increasing incidence Age 7/100,000

More information

Jonathan R. Dillman, MD, MSc. Associate Professor Department of Radiology Cincinnati Children s Hospital Medical Center

Jonathan R. Dillman, MD, MSc. Associate Professor Department of Radiology Cincinnati Children s Hospital Medical Center MR Enterography in Children: Interpretation & Value-Added Jonathan R. Dillman, MD, MSc Associate Professor Department of Radiology Cincinnati Children s Hospital Medical Center Disclosures Crohn s disease

More information

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment

More information

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease

More information

IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease

IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease Immunogenetics (1999) 49: 527 531 Q Springer-Verlag 1999 ORIGINAL PAPER Andrea Nemetz 7 M. Pilar Nosti-Escanilla Tamás Molnár 7 Adorján Köpe 7 Ágota Kovács János Fehér 7 Zsolt Tulassay 7 Ferenc Nagy M.

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency London, 22 February 2007 Doc. Ref. CPMP/EWP/2284/99 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE DEVELOPMENT OF NEW MEDICINAL PRODUCTS FOR

More information

Certain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.

Certain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs. Topic Page: Crohn's disease Definition: Crohn's disease from Benders' Dictionary of Nutrition and Food Technology Chronic inflammatory disease of the bowel, commonly the terminal ileum, of unknown aetiology,

More information

Hydrogen peroxide enhanced ultrasoundfistulography

Hydrogen peroxide enhanced ultrasoundfistulography 874 Department of Gastroenterology, L Sacco University Hospital, Milan, Italy G Maconi F Parente G Bianchi Porro Correspondence to: Professor G Bianchi Porro, Department of Gastroenterology, L Sacco University

More information

Ali Keshavarzian MD Rush University Medical Center

Ali Keshavarzian MD Rush University Medical Center Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting

More information

Medical Policy Title: Serum Antibodies for ARBenefits Approval: 10/12/11

Medical Policy Title: Serum Antibodies for ARBenefits Approval: 10/12/11 Medical Policy Title: Serum Antibodies for ARBenefits Approval: 10/12/11 Diagnosis of Inflammatory Bowel Disease Effective Date: 01/01/2012 Document: ARB0314 Revision Date: Code(s): 83516 Immunoassay for

More information

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014 Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn

More information

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight

More information

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related

More information

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly

More information

INFLAMMATORY BOWEL DISEASE

INFLAMMATORY BOWEL DISEASE 1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These

More information

Nature Genetics: doi: /ng Supplementary Figure 1

Nature Genetics: doi: /ng Supplementary Figure 1 Supplementary Figure 1 Replicability of blood eqtl effects in ileal biopsies from the RISK study. eqtls detected in the vicinity of SNPs associated with IBD tend to show concordant effect size and direction

More information

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy

More information

Auto-antibodies in Patients with Inflammatory Bowel Disease Unclassified

Auto-antibodies in Patients with Inflammatory Bowel Disease Unclassified SHORT PAPER Auto-antibodies in Patients with Inflammatory Bowel Disease Unclassified Batool Mutar Mahdi Department of Microbiology, Al-Kindi College of Medicine, University of Baghdad, Baghdad, Iraq ABSTRACT

More information

Characteristic Phenotypes in Korean Crohn s Disease Patients Who Underwent Intestinal Surgery for the Treatment

Characteristic Phenotypes in Korean Crohn s Disease Patients Who Underwent Intestinal Surgery for the Treatment ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2013.28.4.575 J Korean Med Sci 2013; 28: 575-579 Characteristic Phenotypes in Korean Crohn s Disease Patients Who Underwent

More information

Predicting outcome in IBD by crossing the T s

Predicting outcome in IBD by crossing the T s Oxford Inflammatory Bowel Disease & Hepatology MasterClass Predicting outcome in IBD by crossing the T s Dr James Lee Oxford Inflammatory Bowel Disease & Hepatology MasterClass No financial disclosures

More information

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic

More information

Genetics and Genomics in Medicine Chapter 8 Questions

Genetics and Genomics in Medicine Chapter 8 Questions Genetics and Genomics in Medicine Chapter 8 Questions Linkage Analysis Question Question 8.1 Affected members of the pedigree above have an autosomal dominant disorder, and cytogenetic analyses using conventional

More information

Outcomes of immunosuppressors and biologic drugs in inflammatory bowel diseases: a real life experience

Outcomes of immunosuppressors and biologic drugs in inflammatory bowel diseases: a real life experience Outcomes of immunosuppressors and biologic drugs in inflammatory bowel Treatments and therapeutic approaches in IBD are constantly evolving. The newly emerged biologic treatments are one such evolving

More information

Adalimumab Treatment in Pediatric-Onset Crohn s Disease Patients after Infliximab Failure: A Single Center Study

Adalimumab Treatment in Pediatric-Onset Crohn s Disease Patients after Infliximab Failure: A Single Center Study pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2016.19.2.116 Pediatr Gastroenterol Hepatol Nutr 2016 June 19(2):116-122 Original Article PGHN Adalimumab Treatment in Pediatric-Onset Crohn

More information

ORIGINAL ARTICLE. Surgery for Ulcerative Colitis in Elderly Persons. Changes in Indications for Surgery and Outcome Over Time

ORIGINAL ARTICLE. Surgery for Ulcerative Colitis in Elderly Persons. Changes in Indications for Surgery and Outcome Over Time ORIGINAL ARTICLE Surgery for Ulcerative Colitis in Elderly Persons Changes in Indications for Surgery and Outcome Over Time Gidon Almogy, MD; David B. Sachar, MD; Carol A. Bodian, DrPH; Adrian J. Greenstein,

More information

Comparison of Diagnostic Accuracy and Impact of Magnetic Resonance Imaging and Colonoscopy for the Management of Crohn s Disease

Comparison of Diagnostic Accuracy and Impact of Magnetic Resonance Imaging and Colonoscopy for the Management of Crohn s Disease Journal of Crohn's and Colitis, 2016, 663 669 doi:10.1093/ecco-jcc/jjw015 Advance Access publication January 18, 2016 Original Article Original Article Comparison of Diagnostic Accuracy and Impact of Magnetic

More information

Crohn s disease: is there any link between anal and luminal phenotypes?

Crohn s disease: is there any link between anal and luminal phenotypes? Crohn s disease: is there any link between anal and luminal phenotypes? Timothée Wallenhorst, Charlène Brochard, Jean-François Bretagne, Guillaume Bouguen, Laurent Siproudhis To cite this version: Timothée

More information

CARD15 and Crohn s Disease: Healthy Homozygous Carriers of the 3020insC Frameshift Mutation

CARD15 and Crohn s Disease: Healthy Homozygous Carriers of the 3020insC Frameshift Mutation THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 98, No. 3, 2003 2003 by Am. Coll. of Gastroenterology ISSN 0002-9270/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0002-9270(02)06009-4 CARD15

More information

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features

More information

the clinical characteristics of CD patients with free

the clinical characteristics of CD patients with free Doh et al. BMC Gastroenterology (2015) 15:31 DOI 10.1186/s12876-015-0262-x RESEARCH ARTICLE Open Access The clinical characteristics of patients with free perforation in Korean Crohn s disease: results

More information

PROFILE OF ULCERATIVE COLITIS IN SOUTH INDIAN REGION: KARAIKAL D.BADMAPRIYA*, V.SATHISH KUMAR 1

PROFILE OF ULCERATIVE COLITIS IN SOUTH INDIAN REGION: KARAIKAL D.BADMAPRIYA*, V.SATHISH KUMAR 1 Page47 Available Online through IJPBS Volume 1 Issue 2 APRIL- JUNE 2011 PROFILE OF ULCERATIVE COLITIS IN SOUTH INDIAN REGION: KARAIKAL D.BADMAPRIYA*, V.SATHISH KUMAR 1 * PHARMACIST, GOVERNMENT GENERAL

More information

Strategies for changing the course of Crohn s disease

Strategies for changing the course of Crohn s disease Strategies for changing the course of Crohn s disease Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Where we are now and where we want to be Diagnosis (usually endoscopy)

More information

Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series

Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series CASE REPORT Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series Kaori Fujiwara, Takuya Inoue, Naoki Yorifuji, Munetaka Iguchi, Taisuke Sakanaka, Ken Narabayashi,

More information

Tracking Genetic-Based Treatment Options for Inflammatory Bowel Disease

Tracking Genetic-Based Treatment Options for Inflammatory Bowel Disease Tracking Genetic-Based Treatment Options for Inflammatory Bowel Disease Recorded on: June 25, 2013 Melvin Heyman, M.D. Chief of Pediatric Gastroenterology UCSF Medical Center Please remember the opinions

More information

IBD-Related Lymphoma

IBD-Related Lymphoma IBD-Related Lymphoma Larry Burgart MD Staff Pathologist, Allina Health and Minnesota Gastroenterology Clinical Professor of Pathology, University of Minnesota College of Medicine IBD-Related Lymphoma

More information

Medical Management of Intestinal Strictures

Medical Management of Intestinal Strictures Medical Management of Intestinal Strictures Subrata Ghosh, FRCP, FRCPE, FRCPC, AGAF, FCAHS Professor of Translational Medicine Director of the Institute of Translational Medicine University of Birmingham,

More information

Abstract. Background. Methodology. Results. a11111

Abstract. Background. Methodology. Results. a11111 RESEARCH ARTICLE The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations a11111 OPEN

More information

Surgical Management of IBD in the Age of Biologics

Surgical Management of IBD in the Age of Biologics Surgical Management of IBD in the Age of Biologics Lisa S. Poritz, M.D Associate Professor of Surgery Division of Colon and Rectal Surgery Objectives Discuss surgical management of IBD When to operate

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,

More information

HLA class II and III in Crohn s disease

HLA class II and III in Crohn s disease HLA class II and III in Crohn s disease-contents HLA class II and III in Crohn s disease Associations between HLA-DR1 and TNF microsatellites Rachel van Beem Sept 2002-Jan 2003 Under supervision of E Gomez

More information

Infliximab Prevents Crohn s Disease Recurrence After Ileal Resection

Infliximab Prevents Crohn s Disease Recurrence After Ileal Resection GASTROENTEROLOGY 2009;136:441 450 CLINICAL Infliximab Prevents Crohn s Disease Recurrence After Ileal Resection MIGUEL REGUEIRO,* WOLFGANG SCHRAUT,* LEONARD BAIDOO,* KEVIN E. KIP, ANTONIA R. SEPULVEDA,

More information

Crohn's disease. Appendix N. Clinical Guideline < > 10 October Surgery recurrence rates

Crohn's disease. Appendix N. Clinical Guideline < > 10 October Surgery recurrence rates Crohn's disease Clinical Guideline < > Surgery s 10 October 2012 Commissioned by the National Institute for Health and Clinical Excellence Contents Published by the National Clinical Guideline Centre

More information

Clinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265

Clinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265 Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Gastric Carcinoma in Patients with Crohn Disease: Report of Four Cases

Gastric Carcinoma in Patients with Crohn Disease: Report of Four Cases 311 0361-803X/91/1 572-0311 C American Roentgen Ray Society Seth N. GIick1 Received January 1 7, 1991 ; accepted after re vision March 1 2, 1991. 1 Department of Diagnostic Radiology, Hahnemann University

More information

Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study

Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study Vinciane Dideberg a, Edouard Louis b, Frédéric Farnir c, Sabrina Bertoli

More information

Surgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma?

Surgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma? 17 th Panhellenic IBD Congress Thessaloniki May 2018 Surgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma? Janindra Warusavitarne Consultant Colorectal Surgeon, St

More information